# Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder

> **NCT00343356** · PHASE2 · COMPLETED · sponsor: **LanZhou University** · enrollment: 138 (—)

## Conditions studied

- Bladder Neoplasms

## Interventions

- **DRUG:** Trement

## Key facts

- **NCT ID:** NCT00343356
- **Lead sponsor:** LanZhou University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-06
- **Primary completion:** —
- **Final completion:** 2003-07
- **Target enrollment:** 138 (—)
- **Last updated:** 2006-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00343356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00343356, "Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00343356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*